Wataru Sako

Dr. Wataru Sako

Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2014 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
WSWataru Sako
Wataru Sako
NMNagahisa Murakami
Nagahisa Murakami
YIYuishin Izumi
Yuishin Izumi
RKRyuji Kaji
Ryuji Kaji

1 May 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
WSWataru Sako
Wataru Sako
NMNagahisa Murakami
Nagahisa Murakami
YIYuishin Izumi
Yuishin Izumi
RKRyuji Kaji
Ryuji Kaji

21 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WSWataru Sako
Wataru Sako
NMNagahisa Murakami
Nagahisa Murakami
KMKeisuke Motohama
Keisuke Motohama
YIYuishin Izumi
Yuishin Izumi
RKRyuji Kaji
Ryuji Kaji
Adenosine A2A receptor antagonists are an alternative treatment strategy for Parkinson’s disease. Several randomized placebo controlled studies have tested the effect of A2A receptor antagonist istradefylline, and more robust evidence has been acquired. This meta-analysis aimed to provide evidence for its efficacy and safety on patients with Parkinson’s disease. After a systematic literature search, we calculated the pooled standardized mean difference and risk ratio for continuous and dichotomous variables, respectively. Further, sensitivity analyses were performed to confirm the effect estimated by meta-analyses. Publication bias was assessed by funnel plot and deviation of intercept. Six studies satisfied our inclusion criteria. Istradefylline (40 mg/day) decreased off time and improved motor symptoms of Parkinson’s disease in homogeneous studies. Istradefylline at 20 mg/day decreased off time and improved motor symptoms, but heterogeneity was found in the analysis of the former among studies. There was a significant effect of istradefylline on dyskinesia in homogeneous studies. Publication bias, however, was observed in the comparison of dyskinesia. Other adverse events showed no significant difference. The present meta-analysis suggests that istradefylline at 40 mg/day could alleviate off time and motor symptoms derived from Parkinson’s disease. Dyskinesia might be worsened, but publication bias prevents this from being clear.

1 March 2016 in eNeurologicalSci
Verified
Journal Article
Open access
WSWaka Sakai
Waka Sakai
NMNaoko Matsui
Naoko Matsui
MIMitsuyo Ishida
Mitsuyo Ishida
TFTakahiro Furukawa
Takahiro Furukawa
YMYoshimichi Miyazaki
Yoshimichi Miyazaki
Ryuji KajiRyuji Kaji
Ryuji Kaji
The continuous increase in the number of patients presenting with late-onset myasthenia gravis (LOMG) underscores the need for a better understanding of the clinical course and the establishment of an optimal therapeutic strategy. We aimed to clarify factors associated with clinical outcomes in LOMG. We retrospectively reviewed the clinical profiles of 40 patients with early-onset MG (EOMG) (onset age: 49 years or younger), 30 patients with non-elderly LOMG (onset age: 50-64 years), and 28 patients with elderly LOMG (onset age: 65 years or older) and compared the subgroups according to onset age and thymus status. The evaluated parameters were MGFA classification before treatment, MG-ADL score, complicating diseases, antibody titer, treatment, and MGFA post-intervention status. Elderly LOMG patients showed transition to generalized symptoms at a higher frequency and underwent thymectomy less frequently than EOMG and non-elderly LOMG patients (p < 0.001). The frequencies of crisis and plasmapheresis were significantly lower in thymectomized LOMG patients without thymoma than in thymectomized LOMG patients with thymoma or non-thymectomized LOMG patients (p < 0.01, P < 0.05, respectively). However, the outcome was not significantly different. All of the thymectomized LOMG patients without thymoma presenting with hyperplasia or thymic cyst had a favorable clinical course. Our study showed that elderly LOMG patients are more prone to severity, suggesting that they require aggressive immunomodulatory therapy.

19 October 2023 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
WSWataru Sako
Wataru Sako
YKYuki Kogo
Yuki Kogo
MKMichinori Koebis
Michinori Koebis
YKYoshiaki Kita
Yoshiaki Kita
HYHajime Yamakage
Hajime Yamakage
NHNobutaka Hattori
Nobutaka Hattori
It remains unclear which adjunctive drug for Parkinson’s disease (PD) in combination with levodopa is more effective, tolerable, and safe. We aimed to compare the efficacy, tolerability, and safety among anti-PD drugs from several classes in patients with fluctuating PD who received levodopa through network meta-analysis (NMA). Twelve anti-PD drugs belonging to 4 different drug classes (dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, and an adenosine A2A receptor antagonist) were selected. We systematically searched PubMed, Embase, and the Cochrane Library for eligible randomized controlled trials (RCTs) comparing placebo with anti-PD drug or among anti-PD drugs in patients with PD who experienced motor fluctuations or wearing-off and received levodopa. We included 54 RCTs in the analysis. The NMA was performed under a frequentist framework using a random-effects model. The efficacy outcome was change in daily off-time, and the tolerability outcome was discontinuation due to all causes. Safety outcomes included discontinuation due to adverse events (AEs) and the incidence of AEs, dyskinesia, hallucination, and orthostatic hypotension. According to the surface under the cumulative ranking curve (SUCRA) in the NMA, ropinirole transdermal patch (SUCRA, 0.861) ranked the highest in efficacy, followed by pramipexole (0.762), ropinirole extended release (ER) (0.750), and safinamide (0.691). In terms of tolerability, ropinirole (0.954) ranked the highest, followed by pramipexole (0.857), safinamide (0.717), and ropinirole ER (0.708). Each anti-PD drug had different SUCRA ranking profiles for the safety outcomes. These findings suggest that ropinirole, pramipexole, and safinamide are well-balanced anti-PD drugs that satisfy both efficacy and tolerability outcomes.

1 August 2014 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
WSWataru Sako
Wataru Sako
NMNagahisa Murakami
Nagahisa Murakami
YIYuishin Izumi
Yuishin Izumi
RKRyuji Kaji
Ryuji Kaji